NCT06833307View on ClinicalTrials.gov

The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2026

Conditions
Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis
Interventions
DRUG

SHR-1314

SHR-1314: dose 1 SHR-1314:dose 2 SHR-1314:dose 3

Trial Locations (2)

100045

Capital Medical University Affiliated Children's Hospital, Beijing

200040

Shanghai Huashan Hospital, Shanghai

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY